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EXECUTIVE SUMMARY 
This study provides a detailed description of the costs of providing outpatient human 
immunodeficiency virus (HIV) treatment and care in Kenya. The study was conducted as a 
collaboration between the Kenyan Ministry of Health (MOH) and President’s Emergency Plan 
for AIDS Relief (PEPFAR) agencies. The study undertook a retrospective cost analysis at 29 
outpatient clinics providing HIV treatment and care, estimating the annual treatment costs for 
pre-antiretroviral therapy (pre-ART) and ART patients as borne by the Government of Kenya 
(MOH), PEPFAR, and other local and international partners. Data were collected to show the 
cost differences between different patient types, and to show how costs were distributed across 
funding sources, input types, and programmatic activities over two 6-month periods (January 
2010 to December 2010). 
Care for HIV-positive patients is provided through a predominantly clinician-driven model, with 
chronic care outpatient department services revolving around, and mainly provided in, the 
dedicated ART clinic. Both ART and pre-ART patients were scheduled for regular clinic visits, 
and also received routine CD4 count tests to monitor disease progression. More than 90.0% of all 
ART patients were adults, and almost all were on a triple combination antiretroviral (ARV) 
regimen of two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse 
transcriptase inhibitor (NRTI; NNRTI; first-line therapy in Kenya). 
The following figures are valid estimates of costs for the “typical” HIV treatment clinic, they do 
not reflect the costs of all treatment clinics. Costs varied widely among the sites in the sample, 
with some individual sites costing substantially more or substantially less than the median. 
The median economic unit cost
1
 per patient-year was $248.91 (2011 U.S. dollars [USD]) for 
established adult ART patients; or $120.72 when the cost of ARVs is excluded. The median cost 
per patient-year was $116.71 for pre-ART patients. Costs were higher for established pediatric 
patients ($292.60) compared to established adult patients. Newly initiating ART patients were 
also associated with higher costs than established ART patients at $274.95 for adults and 
                                                 
 
1 
For economic costs, the one-time expense of equipment purchases and similar investments are spread out over the 
useful life of the item, in order to approximate the “long-term” cost of the intervention. 
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$318.73 for pediatric patients. ARVs, the largest single cost component, cost a median of 
$123.03 per year for ART patients. A significant proportion of regimens in the 29 facilities 
included Stavudine, which is a relatively low-cost drug. WHO recommends that countries phase 
out the use of Stavudine, because of its long-term, irreversible side-effects, and Zidovudine or 
Tenofovir are recommended as less toxic and equally effective alternatives. In a theoretical 
scenario, where all Stavudine is replaced with Zidovudine, the median per ART patient among 
29 sites will increase from $240.33 to $292.71. Personnel was the next most substantial cost 
category for both ART and pre-ART patients, accounting for a median of $38.44 and $36.95 per 
patient-year, respectively. 
Comparing the distribution of costs across program activities, clinical care (excluding ARV 
costs) was found to represent the largest component for ART patients (median $36.77 per patient 
year), followed by laboratory services ($19.30). The same was true for the pre-ART patients, 
where clinical care (excluding ARV costs) cost a median of $44.57 per patient year and 
laboratory services cost a median of $19.96 per patient year. It is important to note that activities 
supporting direct service provision—such as management, administration, and monitoring and 
evaluation (M&E)—represented nontrivial additions to the total cost, with a combined median 
cost of $20.43 per patient-year for both ART and pre-ART patients. 
Per-patient financial costs
2
 decreased slightly, by 6.0% over the course of the evaluation (12 
months), with investment costs declining 8.9% and recurrent costs declining 16.2%. The 
composition of expenditures changed over the course of the evaluation. Spending on traditional 
investments—training, equipment, and infrastructure—represented 7.8% of total spending at the 
start of the evaluation, but dropped to approximately 3.5% in the following 12 months. In 
contrast, the costs for ARV drugs and ARV buffer stock (i.e., the additions to the drug supply-
chain inventory to support new patients in treatment), increased as a proportion of total costs.  
ARV drugs increased from 35.9% to 41.2%, while ARV buffer stock increased from 3.7% to 
6.4%. While buffer stock purchases are considered an investment, the timing of buffer stock 
spending is different from other investments and matches the expansion of patient cohorts. The 
                                                 
 
2 
The financial cost perspective shows the actual value of expenditures and other resources used for the clinic as they 
are incurred, in order to reveal time-trends in resource needs. 
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proportion of funding devoted to recurrent costs grew over the course of the evaluation, from 
88.6% to 90.1%.  
PEPFAR was the largest source of support to treatment sites, contributing 49.1% of all resources 
during the first period and 48.1% of all resources during the second period. The Kenyan 
Government (including any budgetary support from the Global Fund and other developmental 
partners)
3
 was the second largest source of funding at the sites included in the study, and its 
funding increased from 45.7% to 47.5% between the first and second period of the evaluation. 
Other funding sources, including private organizations, contributed 5.2% at the beginning of the 
evaluation and 4.4% by the end.  
Major sources of funding assisted sites in somewhat different ways. A major percentage of MOH 
and PEPFAR resources were devoted to ARVs (either dispensed or buffer stock). For MOH 
funding, 44.9% was devoted to purchasing ARVs (dispensed [38.98%] and buffer stock 
[5.89%]), with laboratory supplies as the second largest allocation (30.2%).  While more 
PEPFAR funding was devoted to purchasing ARVs (either dispensed [20.3%] or for buffer stock 
[2.0%]); personnel and other (non-laboratory) supplies were also non-trival costs (19.5% and 
19.3%, respectively). Other resources did not fund any ARV purchases, but provided support for 
personnel (22.1%), equipment (19.7%), training (18.2%) and building use (14.3%).  
Even though treatment is provided free of charge, the findings give evidence of financial burden 
for patients. Based on a survey of patients, adult patients incurred an economic cost-equivalent of 
$52.00 (2011 USD) per year as part of receiving care and treatment. Travel expenses accounted 
for more than 60.0% of the cost
4
. Patients living in rural areas paid, on average, 1.4 times as 
much per year as those living in urban areas. In addition, male and female patients spent a 
considerable amount of time attending the HIV service, an average of 71.6 and 64.8 hours per 
year, respectively. When looked upon as an opportunity cost, this represents approximately 
$46.45 per year
5
 (approximately 5% of the annual minimum wage) of potential lost earnings. 
The substantial resources invested in starting and scaling up HIV treatment programs are a 
                                                 
 
 
4
 The estimates of travel costs are not adjusted for potentially multiple purposes of each trip (e.g. receive health 
services other than HIV related services during the same visit; combine clinic visit with travel for personal reasons). 
5 
Based on the national minimum wage of 6,999 Kenyan shillings (KSh). 
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reflection of the commitment shown by the Government of Kenya, PEPFAR, and other 
international donors and partners to combat HIV/acquired immunodeficiency syndrome (AIDS) 
in Kenya. While program accomplishments are growing each year, and many patients are now 
enjoying the benefits of HIV treatment and care services, the costs of continued support of 
services are substantial, despite reductions in per-patient costs. It will be important to plan for 
and maintain the funding levels needed to continue providing services in the future, as Kenya 
continues to expand access to treatment. 
On the basis of the results of this study, the following recommendations may be helpful to 
consider:  
1) In order to provide successful and cost-effective treatment, it is important to recognize 
the main cost drivers (buffer stock, personnel, and laboratory) so that inefficiencies can 
be addressed in order of importance and relevance to the program. To evaluate and then 
find means of increasing efficiency, the existing cost ranges across sites must be 
considered to account for location, type of patients, and so forth.  
2) Increasing awareness of program costs by expanding this study and carrying out similar 
ones across other HIV programs can provide a deeper understanding of the effort and 
resources needed for optimal treatment. Data can be used for modeling, forecasting, and 
planning for future treatment models.  
3) Furthermore, expanding the scope of the evaluation to cover treatment quality and 
outcomes (i.e., cost-effectiveness analysis) would provide policymakers with key 
information for the decision-making process.  
4) Finally, this study shows that even though treatment is mostly provided for free, patients 
incur a cost to reach available services/treatment. In addition, opportunity costs are 
important to weight in when considering higher frequency of visits. This information 
should be used by policymakers when considering financial health protection 
mechanisms for patients. For example, some policy changes focused on implementing 
strategies to offset out-of-pocket costs for patients from lower socio-economic groups 
may be beneficial (e.g., bringing services closer to patients, drug pick-up zones). 
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1. BACKGROUND 
1.1 HIV Epidemic in Kenya 
The HIV/AIDS epidemic poses a grave challenge to governments, health systems, and 
communities around the world. In 2012, about 2.3 million people (1.9 to 2.7 million) became 
infected with HIV, bringing the global HIV-positive population to roughly 35.3 million (32.2 to 
38.8 million) by the end of the year
 
(UNAIDS, 2013). According to the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), in the same year, an estimated 1.6 million (1.4 to 
1.9 million) lost their lives to AIDS. 
FIGURE 1. ESTIMATED NUMBER OF ADULTS AND CHILDREN WITH HIV IN KENYA 
 
*From NACC/NASCOP, 2011  
Kenya currently faces a generalized HIV/AIDS epidemic, with a national prevalence rate among 
adults in 2012 of 5.6% and 0.9% in children
6 
(NASCOP, 2013). This corresponds to an estimated 
                                                 
 
6
 In the NASCOP KAIS report, adults are defined as all people 15 to 64 years of age and children as 18 months to 14 
years of age. 
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1.2 million adults and 104,000 children infected with HIV
 
(NASCOP, 2013). The prevalence of 
HIV in Kenya is higher among women than men (6.9% and 4.4%, respectively). HIV prevalence 
among urban women (8.0%) is greater than for rural women (6.2%). A similar pattern is found in 
men, with the HIV prevalence rate in urban areas higher than in rural areas at 5.1% and 3.9%, 
respectively (NASCOP, 2013). The HIV and AIDS epidemic in Kenya shows strong provincial 
variation ranging from the highest HIV adult prevalence in Nyanza (15.1%), Nairobi (4.9%), 
Western (4.7%), Coast (4.3%), South Rift (4.3%), Eastern South (4.3%), Central (3.8%) to the 
lowest prevalence in North Rift (3.1%) and Eastern North (2.1%)
7
 (NASCOP, 2013). 
1.2 The Response to the HIV Epidemic in Kenya 
The National AIDS & STIs Control Programme (NASCOP) was created in 1987 by the Ministry 
of Health to co-ordinate the HIV health sector response in the country. NASCOP is a division of 
the ministry of Health and works in collaboration with the National AIDS Control Council 
(NACC), established in 1999, in the Ministry of Special Programmes. The NACC established 9 
regional offices across the country to aid in the coordination and management of the health 
sector’s HIV/AIDS response (NACC, 2012). Kenya’s development of a national policy on 
HIV/AIDS marked a milestone in its response to the epidemic. This effort was reinforced by the 
concurrent establishment of a high level, multisectoral commission (National AIDS Control 
Council) in the Office of the President. While NACC is the strategic leader and coordinator, the 
Constituency AIDS Control Committees, in all the 210 constituencies in the country, are 
responsible for overall leadership and coordination of the response in the country (NACC, 2012). 
HIV/AIDS is also paramount in the nation’s development agenda as specified in Kenya Vision 
2030. Government policy emphasizes the importance of promoting preventive health care as 
opposed to curative intervention, and the necessity to de-link the Ministry of Health from service 
delivery in an effort to improve management of the health institutions within the country. In 
addition, the Kenya Vision 2030 emphasizes the necessity to create a national health insurance 
scheme to promote equity in the nation’s health care financing, and expresses the need for more 
outpost-based approach systems to allow disadvantaged groups to have access to health care 
from preferred institutions (Government of the Republic of Kenya, 2007). The Kenyan 
                                                 
 
7
 No data was available from North Eastern for the NASCOP KAIS 2013 study due to security concerns. 
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government has demonstrated its commitment to fight the epidemic, and to improve the well-
being of its people. 
According to NACC and NASCOP (2012), government recurrent spending on HIV/AIDS nearly 
doubled between 2006–2007 and 2008–2009. The share of foreign funded interventions accounts 
for more than 80.0% of all HIV spending in 2007–2008, bilateral spending on HIV programs 
nearly doubled from 2006–2007 to 2008–2009, increasing from Ksh 20.3 billion (US $305.5 
million) to Ksh 40.0 billion (US $516.0 million)
2
.  
Kenya has benefited from HIV funds from the Global Fund in Round 1 ($2.9 million, 2003 
USD), round 2 ($68.0 million, 2003), round 7 ($46.7 million, 2009), and round 10 ($93.4 
million, 2010), which included components to scale up antiretroviral treatment for individuals 
living with HIV and AIDS, increase access to HIV testing and counseling services, and to 
increase uptake of HIV/AIDS prevention and treatment services (The Global Fund to Fight 
AIDS, Tuberculosis and Malaria, 2011).  
PEPFAR support for the national ART program builds on existing structures and plans on 
working in concert with the MOH and other donors. PEPFAR represents a major commitment by 
the U.S. Government (USG) to undertake comprehensive, evidence-based action to turn the tide 
of the global HIV/AIDS epidemic. Under PEPFAR, Kenya received $92.5 million in fiscal year 
(FY) 2004, $141.3 million in FY 2005, some $208.3 million in FY 2006, $368.1 million in FY 
2007, $534.8 million in FY 2008, $565.0 million in 2009, and $548.1 million in FY 2010 to 
support comprehensive HIV/AIDS prevention, treatment, and care programs. Figures 2 and 3 
document rapid scale-up of ART in Kenya with over 500,000 adult and pediatric patients on 
ART in 2011. Achieving future goals in care and treatment will require cost-conscious program 
management and thoughtful budgeting (PEPFAR, 2012). 
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FIGURE 2. EXPANSION OF ART TO HEALTH FACILITIES 
*Unpublished data by NASCOP 
FIGURE 3. NUMBER OF INDIVIDUALS WHO RECEIVED ART IN KENYA
 
*Unpublished data by NASCOP 
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1.3 The ART Costing Project Study 
The cost of ART service delivery was identified as a priority for evaluation, given the substantial 
resources devoted to supporting HIV treatment and care programs and the deficiencies of the 
existing literature examining HIV treatment costs, which were mainly developed on the basis of 
costing models or excluded key cost components (Kahn, Marseille, & Harris, 2005; Rosen & 
Long, 2006). A detailed understanding of the costs of providing HIV treatment and care within 
Kenya was seen as important information for both country-level decision makers and donors so 
they could inform planning and resource allocation decisions during the initiation, scale-up, and 
maturation of HIV treatment programs. The study is designed in order to estimate the full annual 
per-patient cost of comprehensive HIV treatment and to understand its composition and drivers. 
1.4 ART Costing Studies Funded by PEPFAR 
PEPFAR has supported a series of costing studies across a variety of countries to identify and 
value the discrete cost components dedicated to HIV treatment within a sample of HIV treatment 
facilities. The studies consider diverse settings and delivery systems, and close collaboration 
with in-country teams has facilitated the use of consistent protocols across settings, such that 
data can potentially be aggregated and compared across treatment health facilities with care and 
treatment clinics and countries. 
In Kenya, the costing study was a collaborative effort. A study team was formed with 
participation from CDC, USAID, and the MOH to generate information to assist the MOH, 
PEPFAR, and other country partners in assessing the potential reach of care and treatment 
programs and the financial resources required to support them, as well as informing decisions 
about the service delivery models used for provision of HIV care and treatment services.  
With approximately 1.5 million people infected with HIV in Kenya, considerable resources are 
required to further extend ART coverage and to maintain treatment cohorts in the future. The 
lack of previous cost studies on HIV/AIDS treatment in Kenya makes it difficult for decisions 
makers to anticipate future costs and manage program growth. 
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This national ART costing study has been carried out to generate data for decision makers by addressing 
the following objectives: 
 Estimate the average annual per-person cost of providing comprehensive HIV treatment for 
eligible adult and pediatric clients 
 Evaluate the range of costs for comprehensive HIV treatment across settings and assess how 
components associated with the design and context of treatment programs influence cost 
estimates 
 Assess change in the costs of comprehensive HIV treatment over two time periods and 
estimate the relative magnitude of expenditures for investments and for recurring program 
costs 
 
1.5 Organization of Report 
The report contains two distinct but linked investigations. The first, identified as Program Cost 
Assessment, evaluates the costs of providing comprehensive HIV treatment at the facility level. 
The second, identified as Patient Cost Assessment, evaluates the cost to the patient as they seek 
out and undergo HIV treatment. Section 2 of this report describes the methodology used for the 
Program and Patient Cost Assessments. Section 3 reports the results of the assessments, followed 
by a discussion in section 4. 
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2. METHODS 
2.1 Program Cost Assessment 
2.1.1 Population and Sample 
The population of interest for study included the adult and pediatric patients receiving HIV care 
and ART from the 886 out-patient ART clinics or HIV comprehensive care centers (CCCs) in 
Kenya that report to NASCOP/ PEPFAR and receive PEPFAR support to provide 
comprehensive HIV treatment, defined as the mix of services being offered at each CCC.  The 
study excluded facilities whose ownership was coded as “Other Private” or “Private Medical 
Enterprise”, and facilities whose type did not fall into one of the following categories: Tertiary 
Hospital, Secondary Hospital, Primary Hospital, Other Hospital, Health Centre, and Dispensary. 
The sample was restricted to health facilities with CCCs who had been providing ART for at 
least 18 months as of June 30, 2010.  This criterion reflected the study’s intention to assess 
programs after they had passed the initial start-up phase and to assess, wherever possible, the 
effects of time in programs in a 12-month period. The sampling frame included 630 eligible 
facilities after application of the exclusion criteria. The sample of thirty facilities was randomly 
selected with probability proportional to size (PPS) within strata defined by affiliation: MOH 
sites vs. Non-MOH sites. The frame was implicitly stratified (sorted) by geography and 
represents all facility types. For PPS selection, the measure of size was ART patient volume. At 
the start of the data collection, one facility was excluded from the sample due to the security 
reasons in the region. The majority of HIV treatment clinics included in this study are located in 
urban settings (20 out of 29), and administered by MOH (23 out of 29). Table 1 summarizes key 
features of the study sites. 
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TABLE 1. KENYA FACILITY SAMPLE FOR ART COSTING PROJECT 
Facility Location Area 
ART 
Program 
Started 
Administration 
Health System 
 Level
8
 
BOMU MC* Mombasa Urban 6/1/2004 NGO/FBO Level 4 
BONDO MC Bondo Urban 6/1/2005 MOH Level 4 
BUKAYA HC Mumias Urban 5/1/2008 MOH Level 3 
COAST PGH Mombasa Urban 6/1/2003 MOH Level 5 
COPTIC HOSPITAL* Nairobi Urban 10/1/2004 NGO/FBO Level 4 
GITHUNGURI HC Githunguri Rural 6/1/2006 MOH Level 3 
HOMA-BAY DH*  Homa-Bay Urban 1/1/2004 MOH Level 4 
KAKAMEGA PGH Kakamege Town Urban 1/1/2004 MOH Level 5 
KAUWI SDH Kabati Rural 1/1/2007 MOH Level 4 
KERICHO DH* Kericho Urban 1/1/2004 MOH Level 4 
KIKUYU PCEA  Kikuyu Rural 6/1/2005 NGO/FBO Not Classified 
KOMBEWA DH* Kombewa Rural 1/1/2007 MOH Level 4 
LIVERPOOL VCT Nairobi Urban 1/1/2003 NGO/FBO Not Classified 
LOCO DISPENSARY Nairobi Urban 1/1/2008 MOH Level 2 
MASABA DH Keroka Urban 7/1/2005 MOH Level 4 
MATATA NH Oyugis Town Urban 7/1/2007 NGO/FBO Level 4 
                                                 
 
8
 Levels are defined according to Kenya Essential Package for Health, which is based on a life cycle approach to 
delivery of a comprehensive healthcare package across 6 levels of care. 
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MBITA SDH Mbita Rural 6/1/2006 MOH Level 4 
MERU DH* Meru Urban 6/1/2004 MOH Level 5 
MOSORIOT RHTC Eldoret Urban 1/1/2001 MOH Level 3 
MSAMBWENI DH Msambweni Rural 8/1/2004 MOH Level 4 
MTRH* Eldoret Urban 11/1/2001 MOH Level 6 
NAIVASHA MC Naivasha Urban 01/01/2007 NGO/FBO Level 3 
NAKURU PGH* Nakuru Town Urban 1/1/2002 MOH Level 5 
NYAHURURU DH* Nyahururu Urban 12/1/2005 MOH Level 4 
NYAMIRA DH Nyamira Urban 1/1/2005 MOH Level 4 
ONGO HC Ranen Rural 1/1/2007 MOH Level 3 
PORT VICTORIA 
HOSPITAL 
Port Victoria Urban 1/3/2012 MOH Level 4 
SIAYA DH* Siaya Rural 6/1/2004 MOH Level 4 
YALA SDH Yala Township Rural 1/1/2004 MOH Level 4 
*Indicates sample locations for the Patient Cost Assessment questionnaire. 
 
2.1.2 Defining Comprehensive HIV Treatment 
Comprehensive HIV treatment was defined as both ART and supportive care received by HIV-
positive patients at HIV CCCs.   Adult ART patients receive a standardized regimen of three 
ARVs, which patients take on a daily basis. ART for pediatric (< 15 years) patients is similar to 
adult treatment, with ARV regimens modified using weight- and age-based dosing and using 
liquid formulations as required. Regular clinical assessment and laboratory monitoring are used 
to gauge the response to treatment, and patients are transitioned to second-line ARV regimens as 
indicated by treatment failure, adverse reactions, or drug availability. Supportive care is central 
to HIV management and includes an array of health interventions that vary across sites. These 
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care services may include screening, prophylaxis, and treatment of opportunistic infections, 
sexually transmitted diseases, and HIV-associated cancers; nutritional support; programs to 
promote retention and adherence to therapy; as well as other clinic or community-based activities 
to address health-related concerns for patients. 
Not all HIV-positive patients immediately receive ART upon enrollment in HIV CCCs. 
Transition of pre-ART patients into ART is determined by patient need and treatment guidelines, 
with patient need assessed using standardized clinical or laboratory criteria. Pre-ART patients 
generally have access to a similar range of supportive care services as ART patients, as well as 
regular clinical and laboratory monitoring, though potentially at a different frequency than ART 
patients.  
Differences in patient clinical characteristics, drug regimens, the intensity and type of supportive 
care services required result in differences in the resources needed to provide treatment and care. 
At each facility, the costing study included all services being provided to HIV-positive 
individuals that met three criteria: (1) the primary intent of the service was as a health 
intervention (thus excluding such activities as educational programs and income-generation 
activities), (2) the primary recipient of the service was the HIV-positive individual (as opposed 
to the patient’s family or the general community), and (3) the service was provided in or 
administered by the CCC. 
2.1.3 Patient Types 
While this study considered all HIV-positive individuals enrolled in care or treatment programs 
at the sampled facilities, it is clear that some types of patients consume more resources than 
others. For example, newly initiated ART patients may require more frequent clinical and 
laboratory monitoring in initial months until their treatment is stabilized than do established ART 
patients. Data were collected to subdivide costs according to the types of patients receiving care, 
and results are reported separately for different patient types.  
Table 2 describes patient types and explains why the costs may vary in each case. 
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TABLE 2. PATIENT TYPES  
Pre-ART Versus ART Patients 
Pre-ART patients are HIV-positive, are enrolled within the facility, and are receiving supportive care services and 
periodic follow-up, but are not yet receiving ART. ART patients are HIV-positive, are enrolled within the facility, and 
are receiving ART and associated clinical and laboratory monitoring as well as supportive care services. 
Potential cost differences: It is expected that costs associated with ARVs (dispensed drugs, buffer stock, supply 
chain management) will be the major source of cost differences between the two groups. These differences could 
be reinforced by a greater intensity of clinical and laboratory services received by ART patients. 
Pediatric Versus Adult ART Patients (Subset of ART Patients) 
Pediatric patients are aged 0 to 14 years; adult patients are aged 15 years and older. This distinction is only made 
for ART patients. 
Potential cost differences: Treating pediatric patients poses additional challenges in terms of ARV selection and 
dosing. The major difference is expected to be the different medications used for pediatric patients; however, it is 
also possible that there will be differences in the intensity of clinical and laboratory services. 
Newly Initiated Versus Established Patients (Subset of ART Patients) 
Newly initiated patients have not yet finished their first 6 months of HIV treatment, while established patients have 
been receiving HIV treatment for more than 6 months. This distinction is only made for ART patients. 
Potential cost differences: The major source of cost differences between these groups is expected to be the 
greater intensity of clinical and laboratory services usually devoted to ART patients when they initiate ART and in 
subsequent months, seen in a higher frequency of clinical and laboratory follow-up. 
 
2.1.4 Time Periods 
The study assessed treatment programs over two sequential 6-month periods in order to reveal 
the change in program costs with time. Data on program costs and patient volume were collected 
from January 2010 to December 2010. A maximum of two 6-month periods (12 complete 
months) were collected for each of the facilities included in the sample. 
2.1.5 Perspective of Costing 
This study adopted a programmatic perspective, collecting data on the total costs incurred by 
each treatment program to provide ART and supportive care, and including all sources of 
financial or in-kind support to the program. Medical costs incurred offsite were not included. 
Higher-level overheads—as incurred by the primary implementers, MOH, and USG agencies—
were also excluded in order to focus on those costs incurred at the facility level.  
Analyses of cost data were conducted from both financial and economic cost perspectives. A 
financial cost perspective was employed when expenditures were compared across time periods 
and program maturity, and when budget allocations and the distribution of sources of support are 
the focus of analysis. The financial cost perspective aids planners and decision makers in 
planning resources where the timing of expenditures is important. An economic cost perspective 
was used to evaluate issues and outcomes that relate to a project’s sustainability and 
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comparability (e.g., per-patient costs by cost categories and programmatic activities) over the 
project’s duration. An economic cost approach does not substitute for a financial cost analysis, 
but rather complements it with additional information for decision making. Within the report, 
tables and graphs are labeled to indicate whether the data are reported from an economic or 
financial cost perspective. 
Capital assets are defined as inputs that last for more than one time period. For this study, the 
capital assets included laboratory and other equipment, vehicles, buildings, training, and ARV 
buffer stock. To calculate financial costs, all capital expenses were attributed to the time period 
in which the expenditure occurred. Financial cost analyses are less common and can provide 
insight into how the resource needs of programs change with time, which is important 
information for funders during a rapid scale-up of HIV treatment. To calculate economic costs, 
capital costs are spread over the lifetime of each asset, regardless of purchase time. The value of 
each capital investment is annualized over its expected useful life at a discount rate of 3% per 
annum, consistent with conventional methods of economic evaluation (Drummond, Sculpher, 
Torrance, O’Brien, & Stoddart, 2005; Weinstein, Siegel, Gold, Kamlet, & Russell, 1996). The 
estimated useful life differed by the type of investment (i.e., 30 years for new infrastructure, 
5 years for vehicles and other equipment, 2 years for training, and infinity for buffer stock
9
).  
                                                 
 
 
9
Although individual batches of drugs may expire, efficient supply chain management systems cycle drugs through 
the buffer stock and eliminate spoilage. For this reason, the economic cost of maintaining a buffer stock is 
equivalent to the opportunity cost of having program funds invested in buffer stock (i.e., drug value multiplied by 
3% annual discount rate).  
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2.1.6 Cost Categories10 
Cost data were collected so they could be broken down along three programmatically relevant 
sets of categories. The categories describe each datum by three different attributes: (1) funding 
source, (2) input type or how it was spent (on personnel, supplies, equipment, etc.), and (3) 
program activity. The three categorizations are shown in Table 3 (see also Berruti, 2011). 
TABLE 3. COST CATEGORIZATION MATRIX 
Program Activity Categories 
Training and supervision Supply chain management  
Clinical care M&E and health management information systems (HMIS) 
Laboratory services General administration and operations  
Input Types Categories 
Recurrent expenses Investments 
Personnel Equipment 
ARVs (for dispensing) New infrastructure 
Other drugs Training 
Laboratory supplies  ARVs (for establishment or expansion of buffer stock) 
Other supplies   
Building use   
Travel  
Utilities  
Contracted services  
Funding Source Categories 
Host country government* USG (PEPFAR) 
Other partners  
* The “host country government” category also includes funds from the Global Fund, the World Bank, 
and other foreign sources that are provided through budgetary support to the host country government. 
 
2.1.7 Data Collection and Analysis 
Data were collected at each of the 29 study sites, as well as at organizations providing support to 
the sites (e.g., MOH headquarters, training institutions, ARV procurement agents, technical 
assistance providers), between October 2011 and December 2011. Data were collected through 
retrospective record review, including accounting records, expenditure logs, prescribing records, 
equipment inventories, and routine reporting forms. Additional data were collected through key 
informant interviews to identify the programmatic activities to which resources were devoted, 
and to develop a comprehensive description of the structure and functioning of the HIV 
treatment program at each facility. All data were transcribed into electronic data collection 
                                                 
 
10 
See Berruti (2011) for a detailed explanation. 
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instruments and confirmed through follow-up with key contacts at each site and through 
discussions with key stakeholders in a series of validation meetings. 
Cost data and patient volume data were organized into 6-month time periods from January 1, 
2010 to December 31, 2010. Shared costs (e.g., facility maintenance, administrative and 
managerial overhead) were allocated to the HIV treatment program and then between program 
activities by direct allocation, on the basis of reported percentage effort (for personnel) or 
percentage use (for other inputs). The opportunity cost of using existing building infrastructure 
was estimated as the equivalent rental cost of building space. The cost of ARV buffer stock was 
calculated on the basis of the average number of months of buffer stock held, the incremental 
growth in ART patient volume over the period, the distribution of current ARV regimens, and 
the purchase price of ARVs. For economic cost analyses, capital investments (e.g., laboratory 
equipment) were annuitized over the expected useful life of each item with a 3% discount rate. In 
addition, staff salaries from all sources (including MOH) were taken into account. 
All costs were collected in the original currency, converted to USD at the market exchange rate 
at the time the cost was incurred, and inflated to current price levels. All costs are reported in 
June 2008 USD. Routinely reported indicators from program M&E systems were used to 
calculate the average number of patient-years of treatment provided for each patient type in each 
period. Quantitative analyses were conducted using the Stata SE 12 (StataCorp LP, 2012) data 
analysis and statistical software package. 
2.1.8 Limitations 
Data were collected at each of the 29 study sites, as well as at organizations providing support to 
the sites 
2.2 Patient Cost Assessment  
2.2.1 Sampling Frame 
For a subsample of 10 sites, a convenience sample of 484 adult patients across all sites was 
selected to undertake a voluntary interview on patients’ costs. The 10 sites were selected from a 
random sample of 29 facilities (which were selected for the program cost assessment) using PPS 
within strata defined by affiliation: MOH sites vs. Non-MOH sites (please see Table 1, page 8 
for a list of sampling sites). For PPS selection, the measure of size was ART patient volume. The 
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sample was restricted to those patients that (1) were enrolled in the site’s HIV care and treatment 
program; (2) were aged 18 years or older; and (3) had at least one prior appointment at the clinic 
to ensure they have experienced the HIV care and treatment services offered by the clinic. 
2.2.1 Sample Size 
A key variable calculated from the patient interviews is their annualized treatment 
expenses; however, little is known about the expected variance in patients’ cost between 
facilities and within patient cohorts in Kenya. A study conducted in out-patient HIV treatment 
clinics in Tanzania found an average cost of USD 31.70 with a standard error of 3.68 (MOH 
Tanzania & CDC, 2011). These standard error calculations accounted for the intra-cluster 
correlation of patient costs within sites, which was associated with a design effect of 2.63. To 
estimate what would happen with 10 sites, all combinations of 9 of the 10 sites were evaluated 
and the average cost estimate, standard error, and design effect were calculated. The average 
point estimate was 31.70, the average standard error was 3.88, and the average design effect was 
2.63. These figures indicated that a standard error between 10% and 15% of the estimated costs 
will be obtained if 50 patients are sampled in each of 10 sites (selected at random with one in 
each stratum) for the total of 500 patients. 
2.2.2 Selection Process 
Adult patients attending the site were randomly selected to be interviewed during the time that 
the data collection teams were present at the site. Interviews were confidential and did not collect 
participants’ names, only basic demographic characteristics (i.e., gender, age, location). Patients 
were asked whether they had been interviewed previously for this study, and those who had were 
not interviewed again.  
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3. RESULTS 
3.1 Program Cost Assessment 
3.1.1 Patient Volume at Health Facilities 
The sites included in the study varied in duration of provision of ART services, with start dates 
ranging from January 2003 to May 2008. Across the 29 facilities, the size of each patient cohort 
continued to increase by more than 30 patients per month. Patient volume as measured by the 
number of current patients increased from a median of 2,121 total (pre-ART and ART) patients 
per site at the end of the first 3 months of the study to a median of 2,409 total patients per site by 
the end of the evaluation, 9 months later (see Table 4), with a wide range of patient population 
sizes in sites. 
TABLE 4. PATIENT VOLUME  
Number of Patients After the First 3 Months of Evaluation 
Individuals receiving HIV care (ART + pre-ART) Median (range): 2,121 (97–12,387) 
Individuals receiving ART Median (range): 1,515 (69–8,848) 
Pediatric patients as a percentage of total ART patients Median (range): 7.7% (0.0–16.6%) 
Number of Patients at the End of Evaluation  
Individuals receiving HIV care (ART + pre-ART) Median (range): 2,409 (130–14,034) 
Individuals receiving ART Median (range): 1,721 (93–10,024) 
Pediatric patients as a percentage of total ART patients Median (range): 7.3% (0.2–15.5%) 
Average Quarterly Patient Growth Over Evaluation (Percentage) 
Individuals receiving HIV care (ART + pre-ART) Median (range): 7.1% (-4.9–23.9%) 
Individuals receiving ART Median (range): 7.1% (-4.9–23.9%) 
Average Quarterly Patient Growth Over Evaluation (Absolute) 
Individuals receiving care (ART + pre-ART) Median (range): 93 (-263–937) 
Individuals receiving ART Median (range): 72 (-188–669) 
 
The patients receiving ART were predominantly adults, and the proportion of pediatric ART 
patients slightly fell over time, from a median of 7.7% of all ART patients after 3 months to a 
median of 7.3% of all ART patients at the end of the evaluation (Figure 4). 
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FIGURE 4. AVERAGE NUMBER OF PATIENTS BETWEEN MONTHS 0 AND 12,  
BY PATIENT TYPE 
 
3.1.2 Staffing Model 
The 29 HIV clinics followed the staffing model common with other HIV treatment programs in 
Kenya. This model focused on clinicians (i.e., clinical officers or doctors) providing the majority 
of pre-ART assessments, and initial ART prescriptions, with other clinic staff members playing 
supporting roles. In 12 of 29 sites, nurses were able to perform follow-up ART assessments. The 
variation in the staffing model across sites translated into a wide variation in the clinician-patient 
ratio
11
, ranging from 0.18 to 26.0 clinicians per 1,000 patients, with a median of 4.0 clinicians (at 
the end of the evaluation) (see Table 5). Similarly, the ratio of clinical staff members
12
 to patients 
ranged from 1.1 to 43.5 clinical staff members per 1,000 patients, with a median of 9.6 clinical 
staff at the end of evaluation 
 
                                                 
 
11
 Average number of full-time clinicians per 1,000 patients (ART and pre-ART). 
12
 Clinical staff includes clinicians, nurses, counselors, social workers, pharmacists, and other clinical auxiliaries. 
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TABLE 5. STAFFING RATIOS 
Staffing Ratios 
Clinician-patient ratio Median: 1.2:1,000 (0.18–2.6) 
Clinical staff-patient ratio Median: 5.0:1,000 (1.1–29.6) 
Initial ART Assessment and Prescriptions Provided by: 
Clinicians 23 of 29 (79.3%) 
Nurses   6 of 29 (20.7%) 
Follow-up ART Assessment Provided by: 
Clinicians   17 of 29 (58.6%) 
Nurses   12 of 29 (41.4%) 
 
3.1.3 Clinical and Laboratory Monitoring 
The schedule of clinic visits for pre-ART patients was similar among the 29 facilities. Facilities 
initially evaluated each new HIV-positive patient for disease status and ART eligibility, and if 
the patient was not eligible for ART immediately, he or she was scheduled to return at regular 
intervals—every 3 months or more often—for follow-up and repeat assessment. For patients who 
were initiated on ART, most sites asked patients to return for assessment 2 or 3 times during the 
first month  after initiation and then monthly for 6 months. Subsequently sites differed in the 
regularity of scheduled follow-up for established ART patients, from every two weeks to every 3 
months. However, in all 29 sites, established ART patients were seen at least every 3 months 
(see Table 6).  
TABLE 6. REGULARITY OF SCHEDULED CLINIC VISITS 
Pre-ART Patients 
Every 3 months (or more often) 29 of 29 (100.0%) 
Newly Initiated Adult ART Patients (First 6 Months) 
At baseline, every 3 months (or more often) 29 of 29 (100.0%) 
Established Adult ART Patients (After First 6 Months) 
Every 3 months (or more often) 29 of 29 (100.0%) 
 
CD4 counts were regularly conducted at most of the facilities to assess the eligibility of pre-ART 
patients for ART. For patients on ART, repeat CD4 counts were generally performed every 
6 months to assess treatment response. Blood chemistry and hematology tests to identify side 
effects were performed at most facilities and were more likely to be performed during first 6 
months of treatment. Viral load testing was not regularly conducted at most of the facilities. 
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TABLE 7. REGULARITY OF LABORATORY MONITORING AT FACILITIES
13
 
Scheduled CD4 Counts 
Pre-ART patients 
Every 6 months (or more often) 28 of 29 (96.5%) 
At baseline only (and as needed) 1 of 29 (3.5%) 
Newly initiated adult ART patients (first 6 months) 
At baseline, every 3 months (or more often) 28 of 29 (96.5%) 
At baseline, every 6 months 1 of 29 (3.5%) 
Established adult ART patients (after first 6 months) 
Every 3 months (or more often) 1 of 29 (3.5%) 
Every 6 months (or less often) 28 of 29 (96.5%) 
Blood Chemistry Tests 
Pre-ART patients 
Blood chemistry tests at baseline 21 of 29 (72.4%) 
Blood chemistry tests after first 6 months 14 of 29 (48.3%) 
Newly initiated adult ART patients (first 6 months) 
Blood chemistry tests 23 of 29 (79.3%) 
Established adult ART patients (after first 6 months) 
Blood chemistry tests 15 of 29 (51.7%) 
Hematology Tests 
Pre-ART patients 
Hematology tests at baseline 27 of 29 (93.1%) 
Hematology tests after first 6 months 19 of 29 (65.5%) 
Newly initiated adult ART patients (first 6 months) 
Hematology tests 26 of 29 (89.6%) 
Established adult ART patients (after first 6 months) 
Hematology tests 22 of 29 (75.9%) 
Viral Load Tests 
Pre-ART patients 
Viral load tests at baseline 5 of 29 (17.2%) 
Viral load tests after first 6 months 7 of 29 (24.1%) 
Newly initiated adult ART patients (first 6 months) 
Viral load tests 7 of 29 (24.1%) 
Established adult ART patients (after first 6 months) 
Viral load tests 8 of 29 (27.6%) 
 
3.1.4 Range of Supportive Care Services Provided 
Health facilities differed in terms of the supportive care services provided to ART and pre-ART 
patients. Cotrimoxazole and herpes virus management were part of the care package at all of the 
facilities. Most facilities provided TB treatment onsite, safe water systems, some form of 
psychosocial support, malaria treatment, and pain management. Among less commonly provided 
                                                 
 
13
 The data for this table are based on the reports of key personnel interviewed during site visits and does not 
represent actual utilization of testing (e.g., based on patient chart review), which was outside of scope of this study. 
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services were insecticide-treated bed nets (ITNs) with 18 out of 29 facilities providing those to 
HIV patients, and end-of-life care, which was provided in 16 out of 29 facilities. Activities to 
support ART adherence and retention, which commonly involved clinic staff members or 
volunteers tracking patients in the community when they missed an appointment, were present in 
27 of the 29 facilities (see Table 8). 
TABLE 8. SUPPORTIVE CARE SERVICES FOR ART AND PRE-ART PATIENTS 
Services Provided 
Cotrimoxazole  29 of 29 (100.0%) 
Herpes virus treatment  29 of 29 (100.0%) 
Psychosocial support 28 of 29 (96.5%) 
Follow-up of patients in the community 27 of 29 (93.1%) 
Malaria treatment 26 of 29 (89.7%) 
TB treatment onsite 25 of 29 (86.2%) 
Safe water systems 25 of 29 (86.2%) 
Pain management regularly 24 of 29 (82.8%) 
ITNs 18 of 29 (62.1%) 
End-of-life care 16 of 29 (55.2%) 
 
3.1.5 ARV Regimens 
ARV regimen information for adult ART patients was determined from the ARV dispensing 
records at study sites. The distribution of patients across ARVs is shown in Figure 5, subdivided 
into ARVs forming a part of the nucleoside reverse transcriptase inhibitor (NRTI) backbone and 
NNRTIs/protease inhibitors (PIs).  
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FIGURE 5. DISTRIBUTION OF ARVS WITHIN EACH DRUG CLASS (ADULT ART PATIENTS)  
NRTIs* 
Drug 
Percentage of NRTIs 
Backbone 
 
Lamivudine (3TC) 49.6 
Zidovudine (AZT) 21.1 
Stavudine (d4T) 19.4 
Tenofovir (TDF) 8.7 
Abacavir (ABC) 0.9 
Didanosine (DDI) 0.3 
  
NNRTIs and PIs 
Drug 
Percentage of NNRTIs  
or PIs 
 
Nevirapine (NVP) 69.6 
Efavirenz (EFV) 27.6 
Lopinavir/ritonavir (LPV/r) 2.8 
Nelfinavir (NFV) 
Saquinavir (SQV) 
Indinavir (IDV) 
Ritonavir (RTV) 
 
0.0 
0.0 
0.0 
0.0 
* Note that recommended ARV regimens contain two different NRTIs.  
 
3.2 Unit Cost Per-Patient 
3.2.1 Annual Per-Patient Economic Costs, by Patient Type 
Economic costs—whereby all investment costs are spread out over the useful life of the goods 
and all opportunity costs are considered—give an indication of the likely long-run costs of HIV 
treatment in this setting, without the short-term fluctuations caused by one-time or periodic 
investments. Table 9 shows the median annual economic costs for each patient type over the 
most recent period at each facility. Even excluding ARV costs, greater resources were required 
to support ART patients than pre-ART patients. The costs for established ART patients were 
slightly lower than for newly initiated ART patients, attributable to less frequent and intensive 
clinical follow-up in the established patients. This drop in per-patient costs between newly 
initiated and established ART patients was less pronounced for pediatric patients, reflecting the 
added complexity of ongoing treatment for children. Although the costs of supporting pre-ART 
patients were less than those for ART patients, these costs are nontrivial and their consideration 
is important to program planning.  Median per-patient costs for ART patients are substantially 
3TC 
AZT 
d4T 
TDF 
ABC DDI 
NVP 
EFV 
LPV/
r 
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higher when ARV costs are included. As reported in Figure 5, a significant proportion of 
regimens in the 29 facilities included Stavudine, which is a relatively low cost drug. WHO 
recommends that countries phase out the use of Stavudine, because of its long-term, irreversible 
side-effects, and Zidovudine or Tenofovir are recommended as less toxic and equally effective 
alternatives. In a theoretical scenario, where all Stavudine is replaced with Zidovudine, the 
median per ART patient among 29 sites will increase from $240.33 to $292.71. Additional 
findings from this theoretical scenario are presented in Appendix 1. Looking forward, it is 
predicted that ARV price changes will have a large effect on total resource needs, and for this 
reason, total economic costs are also reported with ARV costs excluded. 
3.2.2 Unit Cost per Patient-Year 
Table 9 and subsequent tables present costs per patient-year. Cost per patient-year is the cost of 
supporting one patient on care or treatment for a full 12 months. This point needs to be taken into 
account when these data are used for planning the expansion of a treatment program. For 
example, if a program was planning a linear scale-up from 1,000 to 2,000 patients over the 
course of a year, this scenario would translate to 1,500 patient-years of treatment, because not all 
patients would need to be supported for the full year. 
TABLE 9. MEDIAN UNIT COST PER PATIENT-YEAR, BY PATIENT TYPE (ECONOMIC COSTS, 2011 
USD) 
Total Cost Pre-ART  All ART  
Newly 
Initiated 
Adult ART  
Established 
Adult ART  
Newly 
Initiated 
Pediatric 
ART 
Established 
Pediatric 
ART 
Including 
ARVs 
Min $51.68 $159.98 $168.81 $158.08 $140.60 $131.78 
Max $250.25 $405.60 $520.04 $400.34 $618.29 $607.44 
Median $116.71 $240.33 $274.95 $248.91 $318.73 $292.60 
Excluding 
ARVs 
Min $51.68 $47.77 $62.46 $46.95 $62.46 $46.95 
Max $250.25 $260.09 $368.42 $259.00 $368.42 $259.00 
Median $116.71 $120.72 $148.34 $120.72 $136.39 $123.59 
 
3.2.3 Distribution of Per-Patient Economic Unit Costs, by Input Type 
Table 10 shows the distribution of median annual economic costs across the different input 
types, subdivided into recurrent costs and investments. While investments may represent 
noteworthy costs at the time they are expended, their relative durability means they make only a 
minor contribution to total economic costs. The costs of dispensed ARVs and, to a much lesser 
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extent, cost of personnel were the most significant cost components for ART patients, while for 
pre-ART patients, personnel and laboratory supplies were the dominant cost components. 
TABLE 10. MEDIAN UNIT COST PER PATIENT-YEAR, BY INPUT TYPE (ECONOMIC COSTS, 2011 
USD) 
Input Types 
Pre-ART 
Patients 
All ART  
Patients 
Newly 
Initiated 
Adult 
ART 
Patients 
Established 
Adult ART 
Patients 
Newly 
Initiated 
Pediatric 
ART 
Patients 
Established 
Pediatric 
ART 
Patients 
R
e
c
u
rr
e
n
t 
C
o
s
ts
 
Personnel $36.95 $38.44 $43.71 $36.47 $43.71 $36.47 
Dispensed ARVs --- $123.03 $122.68 $122.68 $181.53 $181.53 
Other drugs $8.51 $8.51 $8.51 $8.51 $8.51 $8.51 
Laboratory supplies $19.96 $19.30 $19.96 $19.30 $21.11 $19.33 
Other supplies $12.96 $13.57 $16.23 $12.60 $17.95 $12.60 
Building use $6.88 $7.70 $9.88 $7.70 $9.88 $7.70 
Travel $0.38 $0.40 $0.65 $0.38 $0.65 $0.38 
Utilities $1.06 $1.09 $1.09 $1.08 $1.09 $1.08 
Contracted services $2.95 $2.97 $3.04 $2.96 $3.04 $2.96 
ALL RECURRENT COSTS* $112.38 $231.13 $274.11 $239.67 $313.17 $290.89 
In
v
e
s
tm
e
n
ts
 Equipment $1.36 $1.38 $1.40 $1.37 $1.40 $1.37 
Training $1.29 $1.29 $1.29 $1.29 $1.29 $1.29 
New infrastructure $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 
ARV buffer stock --- $0.45 $0.45 $0.45 $0.50 $0.50 
ALL INVESTMENTS* $2.81 $3.36 $3.51 $3.34 $3.63 $3.63 
TOTAL COST* $116.71 $240.33 $274.95 $248.91 $318.73 $292.60 
* Since median costs are presented, the sum of median costs for each input type will not equal median total costs. 
 
Some variation in per-patient costs occurred among sites. Total economic costs per patient-year 
varied between $159.98 and $405.60 for ART patients. With ARV costs excluded, ART patient 
costs varied between $47.77and $260.09. Because this study relied on existing data sources, the 
variation may reflect some inconsistency in the quality of project records. However, these results 
also reflect substantial differences in program operations and in the different resource 
requirements to sustain ART programs in different settings. 
Total costs data for the six program activities (clinical care with and without ARVs) are shown in 
Table 11. Clinical care comprised the largest cost category for both pre-ART and ART patients 
followed by laboratory costs. Reflecting intensity in clinical follow-up, clinical care costs were 
highest for newly initiated adult and pediatric ART patients, followed by pre-ART patients, with 
lower costs for established adult and pediatric ART patients.   Laboratory costs were comparable 
for pre-ART, adult ART (newly or established) and established pediatric ART patients. 
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TABLE 11. MEDIAN UNIT COST PER PATIENT-YEAR, BY PROGRAM ACTIVITY  
(ECONOMIC COSTS, 2011 USD) 
Program Activity 
Pre-ART 
Patients 
All ART 
Patients 
Newly 
Initiated 
Adult 
ART 
Patients 
Established 
Adult ART 
Patients 
Newly 
Initiated 
Pediatric 
ART 
Patients 
Established 
Pediatric 
ART 
Patients 
Training and supervision $1.29 $1.29 $1.29 $1.29 $1.29 $1.29 
Clinical care (excluding ARVs) $44.57 $36.77 $54.86 $36.77 $54.86 $41.14 
Clinical care (ARVs) --- $112.74 $112.42 $112.42 $165.28 $165.28 
Laboratory services $19.96 $19.30 $19.96 $19.30 $21.11 $19.33 
Supply chain management 
(excluding ARVs) --- $7.94 $7.94 $7.94 $7.94 $7.94 
Supply chain management 
(ARVs) 
--- 
$0.42 $0.41 $0.41 $0.46 $0.46 
M&E and HMIS $6.90 $6.90 $6.90 $6.90 $6.90 $6.90 
General administration and 
operations $13.53 $13.53 $13.53 $13.53 $13.53 $13.53 
TOTAL COST* $116.71 $240.33 $274.95 $248.91 $318.73 $292.60 
* Since median costs are presented, the sum of median costs for each category will not equal median total costs. 
 
3.2.4 Change in Total Unit Cost per Patient over the Evaluation Period 
In contrast to Tables 9 through 11, which present economic costs, Table 12 presents financial 
costs, focusing on established adult ART patients. Financial costs provide information on the 
actual timing of resource use as facilities scale-up HIV treatment and care services
14
. The table 
shows median values for the cost per patient-year, comparing the first period with the last period. 
All 29 sites had 12 months of data available; thus, the analysis compares months 0 through 6 
with months 7 through 12.Total costs fell by a median of 6.0%.  There was a median drop of 
16.2% in all recurrent per-patient costs, and a median drop of 8.9% in total investment per-
patient costs. 
  
                                                 
 
14
 This section is for informational purposes only to provide additional information. Tests of statistically significant 
difference have not been conducted. Information on costs between 6 month time blocks become more useful when 
conducting additional rounds of costing studies. 
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TABLE 12. MEDIAN UNIT COST PER PATIENT-YEAR FOR ART PATIENTS, FIRST PERIOD VERSUS 
LAST PERIOD (FINANCIAL COSTS, 2011 USD) 
Input Types 
First Period of 
Evaluation 
Last Period of 
Evaluation 
Percentage 
Reduction in 
Financial Costs 
R
e
c
u
rr
e
n
t 
C
o
s
ts
 
Personnel $47.23 $38.44 18.6% 
Dispensed ARVs $120.13 $123.03 -2.4% 
Other drugs $12.14 $8.51 29.9% 
Laboratory supplies $21.03 $19.30 8.2% 
Other supplies $18.92 $13.57 28.2% 
Building use $9.34 $7.70 17.6% 
Travel $0.48 $0.40 17.7% 
Utilities $1.65 $1.09 34.1% 
Contracted services $1.92 $2.97 -54.8% 
ALL RECURRENT COSTS* $275.91 $231.13 16.2% 
In
v
e
s
tm
e
n
ts
 Equipment $10.60 $0.00 100.0% 
Training $3.81 $2.19 42.6% 
New infrastructure $0.00 $0.00 . 
ARV buffer stock $10.56 $21.76 -106.1% 
ALL INVESTMENTS* $29.29 $26.67 8.9% 
TOTAL COST* $297.96 $279.95 6.0% 
* Since median costs are presented, the sum of median costs for each category will not equal median total costs. 
 
For investment expenditures, it is to be expected that per-patient financial costs would drop with 
time, as much of the infrastructure and equipment required for a site to function needed to be 
present before patients were enrolled, and any expansion in patient numbers should be preceded 
by an expansion in clinic capacity. It is less apparent, however, why recurrent costs should drop 
as sites mature, but a similar rationale—the need to develop capacity before bringing on 
additional patients—also applied to a number of recurrent costs, such as personnel and utilities. 
In addition, it is likely that programs benefited from economies of scale as patient cohorts 
expanded, and the accumulation of program experience led to improved efficiency.  
The purchase of ARVs buffer stock increased significantly (106%) between the first and second 
half of the evaluation. The cost of dispensed ARVs increased slightly (by 2.4%) between the first 
and last periods. The trend of decreasing per-patient financial costs exhibited among ART 
patients was also seen for pre-ART patients, with the median financial cost per patient-year 
dropping from $159.14 in the first period of evaluation to $118.92 in the last period, an overall 
reduction of 25.3%. Figure 6 shows the average financial costs per patient-year for two 
sequential 6-month periods at the 29 sites for each of the five patient types. As can be seen, per-
patient costs dropped slightly between months 0 through 6 and months 7 through 12, with 
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established patients showing the least decline. The data underlying Figure 6 are shown in Table 
13, and also report financial costs excluding ARV costs 
FIGURE 6. REDUCTION IN AVERAGE ANNUALIZED UNIT COST PER PATIENT-YEAR FROM PERIOD 1 
TO PERIOD 2 (FINANCIAL COSTS, 2011 USD) 
 
TABLE 13. REDUCTION IN MEDIAN ANNUALIZED UNIT COST PER PATIENT-YEAR WITH PROGRAM 
MATURITY, BY PATIENT TYPE (FINANCIAL COSTS, 2011 USD) 
Patient Type Period 1 Period 2 
Including ARV Drugs 
Pre-ART $159.14 $118.92 
New adult ART $336.58 $298.97 
Established adult ART $292.32 $281.09 
New pediatric ART $394.07 $353.70 
Established pediatric ART $344.63 $299.13 
Excluding ARV Drugs 
Pre-ART $159.14 $118.92 
New adult ART $190.38 $155.59 
Established adult ART $156.49 $133.56 
New pediatric ART $187.84 $155.59 
Established pediatric ART $162.28 $129.87 
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3.3 Site-Level Costs
15
 
Per-patient costs decreased sharply during the evaluation, and total site-level financial costs also 
fell at the majority of sites. With ARVs included, the median total cost per site in the first 6-
month period was $251,404.28, compared to $235,268.31 in the last period. Total median cost 
without ARVs was $156,244.60 for the first period and $114,903.60 for the second. The mean 
percentage decrease in costs was 12.9% and 29.1% between the two periods, including and 
excluding ARVs, respectively. Site-level costs also changed in terms of their distribution across 
cost categories. Figure 7 shows how the distribution of site-level costs across input types 
changed between the first and last periods. 
  
                                                 
 
15
 Refers to the total cost of the health facility. 
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FIGURE 7. DISTRIBUTION OF SITE-LEVEL COSTS ACROSS INPUT TYPES, PERIOD 1 VERSUS 
PERIOD 2 (FINANCIAL COSTS, 2011 USD) 
 
 
* Other Recurrent Cost includes other drugs, laboratory supplies, other supplies, building use, travel, utilities, and contracted 
services. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spending on training, equipment, and infrastructure (traditional investments) represented 7.8% 
of total costs in the first period, and this figure dropped to 3.5% in the last period. ARV buffer 
stock investment increased as a percentage of total costs, from 3.7% to 6.4%. The percentage 
spent on most recurrent costs increased between the first and last periods, due to the increasing 
proportion of total spending devoted to dispensed ARVs, from 35.9% to 41.2%.  
18.3% 
41.2% 
30.7% 
1.7% 
1.4% 
0.3% 
6.4% 
Personnel ARV Drugs
Other Recurrent Cost* Training
Equipment New Infrastructure
ARV Buffer Stock
Input Types Period 1 Period 2  
Personnel 20.0% 18.3% 
ARV Drugs 35.9% 41.2% 
Other Drugs 5.1% 5.2% 
Laboratory 10.6% 10.8% 
Other Supplies 7.4% 6.2% 
Building Use 5.4% 4.9% 
Travel 0.7% 0.5% 
Utilities 1.2% 1.0% 
Contracted Services 2.2% 2.1% 
All Recurrent Cost 88.6% 90.1% 
Equipment 5.6% 1.4% 
Training 1.9% 1.7% 
New Buildings and 
Renovation 
0.3% 0.3% 
ARV Buffer Stock 3.7% 6.4% 
All Investments 11.4% 9.9% 
20.0% 
35.9% 
32.6% 
1.9% 
5.6% 
30.0% 
3.7% 
                Period 1                              Period 2 
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Figure 8 shows how the distribution of resources across programmatic activities changed 
between the first and second periods. Because ARV expenditures for dispensing and buffer stock 
investment represented such a large portion of total costs, these expenditures have been separated 
from the clinical services and buffer stock categories in the figure. As might be expected, clinical 
care represented the major programmatic activity in terms of resource consumption. With ARVs 
included, clinical care accounted for 29.0% of all costs in the first period and 30.9% of all costs 
in the last period. Supply chain costs (including ARVs) increased as a percentage of total costs, 
from 5.1% to 6.3%, mainly due to an increase in patients’ volume and spending on buffer stock 
during the last period. M&E and HMIS represented a small but nontrivial cost category. 
FIGURE 8. DISTRIBUTION OF SITE-LEVEL COSTS ACROSS PROGRAMMATIC ACTIVITY CATEGORIES, 
PERIOD 1 VERSUS PERIOD 2 (FINANCIAL COSTS, 2011 USD) 
 
 
 
 
 
 
 
 
 
 
 
Programmatic Activity Categories Period 1 Period 2 
Training and supervision 1.9% 1.7% 
Clinical care (excluding ARVs) 29.5% 25.9% 
Clinical care (ARVs) 32.9% 37.7% 
Laboratory 10.6% 10.8% 
Supply chain (excluding ARVs) 6.2% 6.3% 
Supply chain (ARVs) 3.4% 5.9% 
M&E and HMIS 3.9% 3.4% 
General administration and operations 10.4% 7.4% 
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45.7% 49.1% 
5.2% 
47.5% 48.1% 
4.4% 
GOK* USG (PEPFAR) Other
3.3.1 Resources Provided by Different Funding Sources 
Figure 9 shows the distribution of total site-level costs across funding sources, comparing the 
first and last periods. USG funding, through PEPFAR, represented 49.1% and 48.1%, 
respectively, during the first and last period of the evaluation. Different funding sources 
contributed to treatment programs in a variety of ways, and this is shown in Table 14. The 
majority of resources from the MOH were devoted to ARVs (44.9% when summing spending for 
dispensed drugs and buffer stock) and laboratory costs (at 30.2%). The majority of PEPFAR 
funding was also devoted to ARVs—22.3% (combining dispensed drugs and buffer stock). 
Personnel was the next largest cost category, at 19.5%, then other (non laboratory) supplies and 
laboratory supplies at 19.3% and 16.4% of total PEPFAR funding, respectively. 
 
FIGURE 9. DISTRIBUTION OF SITE-LEVEL COSTS ACROSS FUNDING SOURCES, PERIOD 1 VERSUS 
PERIOD 2 (FINANCIAL COSTS, 2011 USD) 
 
 
 
 
Funding Source Categories Period 1  Period 2 
MOH* 45.7% 47.5% 
USG (PEPFAR) 49.1% 48.1% 
Other (Private Organizations) 5.2% 4.4% 
* Other includes any budgetary support from the Global Fund and other development 
partners. 
 
 
 
                Period 1                                      Period 2 
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33.5% 
66.5% 
Male Female
40.0% 
60.0% 
Urban Rural
TABLE 14. DISTRIBUTION OF TOTAL FUNDING ACROSS INPUT TYPES, 
BY FUNDING SOURCE (FINANCIAL COST, 2011 USD) 
Input Types MOH* 
USG 
PEPFAR 
Other All Funding 
R
e
c
u
rr
e
n
t 
C
o
s
ts
  
Personnel 9.5% 19.5% 22.1% 19.1% 
Dispensed ARVs 39.0% 20.3% 0.0% 38.4% 
Other drugs 6.9% 3.5% 2.7% 5.1% 
Laboratory supplies 30.2% 16.4% 1.3% 10.7% 
Other supplies 1.0% 19.3% 0.6% 6.8% 
Building use 3.9% 5.3% 14.3% 5.1% 
Travel 0.1% 0.6% 3.0% 0.6% 
Utilities 0.9% 0.7% 8.3% 1.1% 
Contracted services 1.0% 2.4% 8.7% 2.1% 
ALL RECURRENT COSTS 92.5% 88.0% 61.0% 89.1% 
In
v
e
s
tm
e
n
ts
 Equipment 1.0% 7.1% 19.7% 3.7% 
Training 0.6% 2.8% 18.2% 1.8% 
New infrastructure 0.1% 0.2% 1.1% 0.3% 
ARV buffer stock 5.9% 2.0% 0.0% 5.1% 
ALL INVESTMENTS 7.6% 12.0% 39.0% 10.9% 
TOTAL 100.0% 100.0% 100.0% 100.0% 
* MOH includes any budgetary support from other development partners, such as the World Bank, 
Global Fund, and so forth. 
 
3.4 Patient Cost Assessment 
3.4.1 Demographic Characteristics 
Figures 10 and 11 provide a summary of key demographic information for participants of the 
patient’s survey (n=484). Participants included patients from 10 preselected HIV treatment 
facilities in Kenya. Because of the selection process, the sample is not statistically representative; 
rather, the main purpose of sampling was to capture a generally representative sample of patients 
from publicly funded HIV treatment sites in Kenya. 
FIGURE 10. DEMOGRAPHIC CHARACTERISTICS 
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Approximately 60.0% of respondents resided in rural areas and 40% resided in urban areas. The 
disparity between genders was more pronounced, with 66.5% female and 33.5% male 
respondents, reflecting the higher uptake of ART services by women. Slightly over one-third of 
the rural respondents were male (63.1% females) and males represent only 28.3% (71.4% 
females) in urban areas. The age of participants varied from 18 to 76 years old, with a median 
age of 40. Figure 11 summarizes the distribution of age of respondents. On average, males were 
older than females (42 years and 39 years old respectively), and rural residents were older than 
urban residents (41 and 38 years old, respectively).  
FIGURE 11. AGE DISTRIBUTION 
 
3.4.2 Facility Characteristics 
Facilities differed in term of patient types and the duration of their treatment in the 
establishment. Figure 12 presents the mean duration of HIV treatment in years, broken down by 
facility. The overall mean for the entire sample equals 3.33 years, with individual facility means 
ranging between 2.14 and 4.60 years. Figure 12 also includes the percentage of respondents 
taking ARV drugs as part of the HIV treatment, by facility. Percentages varied from 67.0% to 
96.0% between facilities, with an overall percentage of 89.2% of patients taking ARV drugs. 
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FIGURE 12. FACILITY TREATMENT CHARACTERISTICS 
 
Figure 13 shows a per-facility analysis of the length of time that patients have taken ARV drugs 
at each treatment facility. In the overall sample, respondents reported an average of 3.16 years on 
ARV drugs, but individual facility means varied from 1.93 to 4.02 years. 
FIGURE 13. LONGEVITY OF PATIENT ON ARV DRUGS, BY FACILITY 
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3.4.3 Socio-Economic Characteristics 
Due to the nature of the survey, the ART patient questionnaire (PQ) did not collect information 
on household income or household consumption, but on dwelling conditions (i.e., floor 
construction, wall construction, roof construction, source of water, type of toilet, availability of 
electricity) and asset ownership (i.e., radio, television, phone/mobile, iron, fridge, bicycle, 
motorbike/scooter, car/truck). Tables 15 and 16 list all the variables on assets and living 
conditions used for constructing the wealth score and the percentage of urban and rural 
households that reports owing these items. A composite measurement of economic well-being or 
wealth was obtained by calculating household (HH) wealth scores using principal component 
analysis (as a proxy measure of economic status).
16
 In order to define the socio-economic groups, 
households are ranked in terms of their wealth scores and clustered them into five groups. The 
lowest quintile defined the “poorest” group and the highest quintile defined the “least poor” 
group for the analysis. 
A summary of household assets is shown in Tables 15 and 16. The majority of the respondents 
(81.4%) owned a radio, and almost 84% had a phone or a mobile phone. Around 6% of 
respondents owned a motorcycle, and almost one-fourth owned a bicycle. It was more common 
in rural areas to own a bicycle, while cars ownership was almost twice as common among urban 
respondents. Additionally, respondents living in urban areas are more likely to own a radio, 
television, phone/mobile phone, iron, and/or a refrigerator. 
TABLE 15. PERCENTAGE OF HOUSEHOLDS REPORTING OWNERSHIP OF VARIOUS ASSETS, 
BY PLACE OF RESIDENCE 
Asset 
Urban 
(n = 194) 
Rural 
(n = 290) 
Total 
(n = 484) 
Radio 81.4% 74.1% 77.1% 
Television 60.3% 26.2% 39.9% 
Phone/mobile phone 85.1% 83.1% 83.9% 
Iron 55.7% 41.0% 46.9% 
Refrigerator 17.5% 2.1% 8.3% 
Bicycle 16.0% 29.7% 24.2% 
Motorbike/scooter 4.1% 6.9% 5.8% 
Car/truck 10.8% 5.5% 7.6% 
 
                                                 
 
16
 These indices are often referred to as household wealth scores. Please see Filmer and Pritchett (1999 and 2001); 
Montgomery et al. (2000); and Khan et al. (2006) for detailed information on how to construct wealth indices. 
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A similar trend presents households dwelling conditions (Table 16). Overall, households residing 
in urban settings tend to have a higher standard of living. While 77.3% of urban respondents had 
finished floors, only 31.7% did in rural areas. Similarly, a higher percentage of urban patients 
reported having cement block or stone walls than rural patients. Furthermore, urban respondents 
had better access to piped/bottled or tap water, 57.2% compared with only 21.4% of respondents 
in urban and rural areas, respectively. Urban patients also reported better access to toilet facilities 
than their rural counterparts. All urban respondents had a flushable toilet, a pit toilet/latrine, or 
ventilated improved pit (VIP) latrine in urban areas (100%), while almost 5% of urban 
respondents reported not having a toilet. In addition, there was an notable difference between 
urban and rural households with electricity: 58.9% versus 15.5%, respectively. This considerable 
disparity provides meaningful insight into the large differences in ownership of other items on 
the list that require electricity: telephone, phone/mobile phone, iron, and refrigerator. 
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TABLE 16. PERCENTAGE OF HOUSEHOLDS REPORTING DWELLING CONDITIONS, 
BY PLACE OF RESIDENCE 
Dwelling Condition 
Urban 
(n = 194) 
Rural 
(n = 290) 
Total 
(n = 484) 
Floor 
Natural floor (earth, sand, dung) 22.2% 67.2% 49.2% 
Rudimentary floor (wood planks, palm, bamboo) 0.5% 1.0% 0.8% 
Finished floor (parquet, polished wood, vinyl, asphalt strips, ceramic tiles, 
cement, carpet) 77.3% 31.7% 50.0% 
Walls 
Natural walls (grass, pole, mud) 18.0% 45.5% 34.5% 
Rudimentary walls (sun-dried bricks) 0.0% 11.1% 6.6% 
Finished wall (baked bricks, wood, timber, iron/metal sheeting) 11.9% 23.8% 19.0% 
Finished wall (cement blocks) 39.2% 13.4% 23.8% 
Finished wall (stones) 30.9% 6.2% 16.1% 
Roof 
Natural roof (grass, leaves, mud) 3.1% 14.8% 10.1% 
Rudimentary roof (iron sheets) 85.0% 83.8% 84.3% 
Finished roof (tiles) 8.8% 0.3% 3.7% 
Finished roof (concrete) 0.5% 0.4% 0.5% 
Finished roof (asbestos) 2.6% 0.7% 1.4% 
Source of drinking water 
Piped/bottled water 57.2% 21.4% 35.7% 
Neighbor's tap or public tab 23.2% 6.5% 13.2% 
Open well 2.6% 12.8% 8.7% 
Covered well or borehole 7.2% 16.2% 12.6% 
Surface water: spring, river/stream, pond/lake, dam, rainwater 9.8% 43.1% 29.8% 
Toilet 
Flushable toilet 0.284 1.7% 12.4% 
Pit toilet/latrine, VIP latrine 0.613 65.5% 63.8% 
Traditional pit toilet 0.103 27.9% 20.9% 
No facility/bush/field 0 4.8% 2.9% 
Household 
Electricity 59.8% 15.5% 33.3% 
 
By using the weight scores from the Kenya Demographic and Health Survey (2008-2009) 
(KDHS, 2010), it is possible to compare the socio-economic status (SES) characteristics of the 
population in our sample with the nationally representative sample and have a better 
understanding of any existing sample differences. Table 17 shows that study sample was 
generally similar to the nationally representative sample. Approximately 29.9% of urban 
respondents in the study sample belonged to the urban national lowest quintile, and 7.7% fell in 
the fifth wealthiest quintile, indicating that urban PQ patients generally have a lower SES 
relative to the national sample. Among rural PQ patients only 5.9% belonged to the national 
lowest quintile.  It should also be noted that only two of the sites were in rural areas so some 
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rural patients were attending urban sites. These patients are likely a particular type of rural 
patient who can afford travel into urban areas for care.  
TABLE 17. DISTRIBUTION OF PQ RESPONDENTS IN EACH KENYA DHS SES QUINTILE, 
BY PLACE OF RESIDENCE 
Kenya DHS Quintiles 
Urban 
(n = 194) 
Rural 
(n = 290) 
Total 
(n = 484) 
Poorest 28.9% 5.9% 10.4% 
Second poorest 18.0% 24.8% 18.2% 
Third poorest 26.8% 16.2% 25.8% 
Fourth poorest 18.6% 27.6% 22.7% 
Least poor 7.7% 25.5% 22.9% 
 
Another way to examine how the PQ sample compares with the national population is through 
education levels. Table 18 shows considerable variation between urban and rural patients, both in 
the PQ and the THMIS sample population. Also, there is a discernible difference between 
education levels of the PQ sample and the THMIS sample; in urban areas, 82.1% and 70.0% 
reported at least completing primary school in PQ and THMIS, respectively. Comparable 
difference between PQ and THMIS has been reported in rural areas; 59.9% and 45.0% reported 
at least completed primary school in PQ and THMIS, respectively. The main distinction between 
samples was the “no education” category, with 7.8% of urban and 19.2% of rural patients from 
the PQ, versus 16.4% urban and 33.5% of THMIS respondents. As expected, the figures also 
showed overall higher education levels for urban populations in both samples. 
TABLE 18. PERCENTAGE OF REPORTING EDUCATION LEVELS, 
BY SAMPLE AND PLACE OF RESIDENCE 
Education Level 
Urban Rural 
PQ 
(n = 218) 
THMIS 
(n = 1,835) 
PQ 
(n = 282) 
THMIS 
(n = 6,662) 
No education 7.8% 16.4% 19.2% 33.5% 
Some primary school 10.1% 13.6% 20.9% 21.5% 
Completed primary school 58.7% 45.5% 53.2% 35.7% 
Some secondary school 8.7% 16.2% 2.8% 7.9% 
Completed secondary school or any 
university 
14.7% 8.3% 3.9% 1.4% 
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3.4.4 Out-of-Pocket Payments 
The total patient cost, also known as out-of-pocket payments, associated with HIV treatment and 
care was calculated as the sum of (1) travel cost
17
, (2) accommodation, (3) drug cost, (4) 
treatment cost, (5) gift or informal payments, and (6) other payments made by patients (i.e., 
laboratory test). Table 19 presents the total and partial annual cost by patients’ place of residence 
and patients’ gender. On average, patients reported an annual cost of $52.46 (across all patients). 
However, the cost range was wide, across location and gender, with males having, on average, 
higher patient costs. Total annual patient cost ranged between $47.87 and $51.19 for females and 
between $29.92 and $72.20 for males in urban and rural areas, respectively. The main drivers of 
the patients’ cost were travel and other costs (i.e., babysitting). 
TABLE 19. TOTAL AVERAGE PATIENT COST, BY PLACE OF RESIDENCE AND GENDER (USD 2011) 
Out-of-Pocket 
Patient Costs 
Urban 
(n = 194) 
Rural 
(n = 290) 
Total 
(n = 484) 
Male 
(n = 55) 
Female 
(n = 139) 
Male 
(n = 107) 
Female 
(n = 183) 
Male 
(n = 162) 
Female 
(n = 322) 
Travel cost $25.48  $19.30  $51.66  $33.74  $42.77  $27.51  
Accommodation cost $1.10  $0.00  $2.21  $1.05  $1.83  $0.60  
Drug cost $1.14  $0.73  $0.63  $2.67  $0.80  $1.83  
Treatment cost $1.39  $3.64  $1.73  $0.69  $1.61  $1.96  
Informal cost $0.81  $0.00  $0.00  $0.02  $0.28  $0.01  
Other cost $0.00  $24.19  $15.96  $13.01  $10.54  $17.84  
TOTAL COST $29.92  $47.87  $72.20  $51.19  $57.84  $49.76  
 
The spending pattern varied widely by SES and place of residence (Table 20). Only among the 
wealthiest patients, we observed that patients reported higher expenditures in urban areas than in 
rural ones. In contrast, rural respondents of all other SES groups spent considerably more money 
for HIV access to services than their counterparts in urban areas. These cost differences may be 
explained by additional travel costs and less available treatment options for patients residing in 
rural settings. 
 
 
 
                                                 
 
17
 The estimates of travel costs are not adjusted for potentially multiple purposes of each trip (e.g. receive health 
services other than HIV related services during the same visit; combine clinic visit with travel for personal reasons). 
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TABLE 20. TOTAL AVERAGE PATIENT COST, BY PLACE OF RESIDENCE AND SES (USD 2011) 
PQ Quintiles 
Urban 
(n = 194) 
Rural 
(n = 290) 
Total 
(n = 484) 
Poorest $18.76 $54.80 $53.66 
Second poorest $34.79 $53.44 $46.44 
Third poorest $26.15 $49.47 $61.26 
Fourth poorest $23.37 $82.5 $36.04 
Least poor $119.09 $54.47 $66.04 
 
Patients accessed HIV care and treatment services using different modes of transportation (see 
Table 21). Most of the patients traveled to the facility by bus in urban and rural areas, accounting 
for 62.9% and 78.6%, respectively. The second most popular mode of transportation (15.9%) 
was walking (26.3% and 9.0% in urban and rural areas, respectively). 
TABLE 21. PATIENTS TRANSPORTATION, BY PLACE OF RESIDENCE 
Transportation 
Urban 
(n = 194) 
Rural 
(n = 290) 
Total 
(n = 484) 
Bus 62.9% 78.6% 72.3% 
Walk less than 1 hour 22.7% 4.5% 11.8% 
Walk more than 1 hour 3.6% 4.5% 4.1% 
Bicycle 1.5% 3.8% 2.9% 
Car or motorbike/scooter 2.6% 2.8% 2.7% 
Other 6.7% 5.8% 6.2% 
 
Females spent more time on HIV services (e.g., during commuting, at the waiting room); the 
difference was more pronounced in urban areas (58.1 and 78.1 hours/year for male and females, 
respectively (see Figure 14). On the basis of the Kenya minimum wage estimate (6,999 KSh per 
month)
18, the annual patients’ opportunity cost of the total time spent for treatment was $46.45 
(USD, June 2011); approximately 5% of the annual national minimum wage. 
 
 
 
 
                                                 
 
18
 Kenya National Bureau of Statistics. 
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FIGURE 14. ANNUAL AVERAGE HOURS SPENT ON CLINIC VISITS, 
BY PLACE OF RESIDENCE AND GENDER 
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4. DISCUSSION 
The median economic cost per patient-year at these 29 Kenyan sites was $248.91 (2011 USD) 
for established adult ART patients ($120.72 with the cost of ARVs excluded). The median cost 
per patient-year was $116.71 for pre-ART patients. Costs were higher for newly initiated adult 
and newly initiated pediatric patients compared to established patients. ARVs cost a median of 
$123.0 for ART patients, was the largest single cost component for these patients.  With ARVs 
excluded, personnel costs were the most substantial category for ART patients and pre-ART 
patients, at a median of $38.44 and $36.95, respectively.   
A significant proportion of regimens in the 29 facilities included Stavudine, which is a relatively 
low-cost drug. Zidovudine or Tenofovir are increasingly replacing stavudine as they are less 
toxic and equally effective alternatives.  Over time as Stavudine is replaced with Zidovudine, the 
median cost per ART patient among these sites will increase from $240.33 to $292.71.  
These economic costs give a sense of the long-run costs of HIV treatment and associated care, 
yet the financial costs over the course of the study were higher, since some sites incurred in 
building infrastructure and renovations, training staff members, standardize clinical routines, and 
expand nascent treatment cohorts. Per-patient costs dropped slightly, by 6.0% over the course of 
the evaluation, with investment costs dropping by 8.9% and recurrent costs dropping by 16.2%, 
largely due to rising numbers of patients.  
Changes in share of site costs were also noted. Spending on traditional investments—training, 
equipment, and infrastructure—represented 7.8% of total spending at the start of the evaluation, 
but decreased to 3.5% by the end of the evaluation. The costs of ARV buffer stock purchases 
increased from 3.7% to 6.7% of site costs, while overall ARV costs increased from 35.9% to 
41.2% as a proportion of total costs. While buffer stock purchases are considered an investment, 
the timing of buffer stock spending differs from other investments, and matches the expansion of 
patient cohorts. As patient volume continued to grow in later periods, the need to continually 
expand ARV inventories increased as well. The proportion of funding devoted to recurrent costs 
grew over the course of the evaluation, from 88.6% to 90.1%, driven by the increase in spending 
on dispensed ARVs. 
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PEPFAR was one of the major sources of financial support at the sites included in the study, with 
funding at 49.1% and 48.1% of total funding during the first and last period of the evaluation. 
Funding from the MOH (which includes any budgetary support from Global Fund and other 
development partners) increased from 45.7% to 47.5% between the two periods. Other funding 
came in at 5.2% at the start of the evaluation and decreased to 4.4% by the end.  
Different funding sources supported sites in diverse ways. The majority of MOH funding (44.9 
%) was devoted to purchasing ARVs (either dispensed [39.0%] or for buffer stock [5.9%]), and 
laboratory costs were also noteworthy (30.2%). PEPFAR support came mainly through the 
purchase of ARVs, paying program personnel, and other supplies (non laboratory), which 
represented 20.3%, 19.5%, and 19.3% of total government spending, respectively. 
The substantial resources invested in starting and scaling-up HIV treatment programs are a 
reflection of the commitment shown by the Government of Kenya, PEPFAR, and other 
international donors and partners to combat HIV/AIDS in Kenya. While program 
accomplishments are growing each year and increasing numbers of patients are benefiting from 
effective HIV treatment and care services, the costs of supporting and increasing services are 
substantial. The Study found that recurrent costs accounted for the large majority of total costs 
and only modest decreases in per patient costs were observed between the two study periods. 
These findings imply that further increases in number of patients are not likely to lead to 
significant economies of scale. Furthermore, potential changes in unit costs and/or guidelines 
affecting main cost drivers identified by the study (i.e., as ARV drugs, personnel, and laboratory) 
are likely to have large effects on per patient costs.  Despite recent reductions in the per-patient 
costs, the ability to maintain and increase the number of patients being treated—with the ultimate 
goal of achieving universal access (United Nations, 2006)—requires efficient use of health 
resources and the planning tools to support this objective. 
Finally, the study investigates the role individuals play in financing the HIV/AIDS treatment 
programs through out-of-pocket payments. None of the patients selected refused to participate in 
the survey, which reduces the possible bias that these patients may differ systematically from 
participating patients. Even though treatment is largely provided for free, the findings give 
evidence for policymakers for designing financial health protection mechanisms for patient 
burden. Adult patients spent an average of $52.00 (2011 USD) per year on care and treatment. 
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The majority of the spending (63.5%) accounts for travel expenses. Patients living in rural areas 
pay on average 1.4 times as much per year as those living in urban ones. Males living in urban 
areas spent 62.5% of what females spent, while the situation among those living in rural areas is 
reversed with females spending 70.9% of what males spent. Patients with highest socioeconomic 
status spent on average more for HIV/AID care and treatment. In addition, male and female 
patients spent a substantial amount of time at the HIV service, an average of 71.6 and 64.8 hours 
per year, respectively. This represents time which could have been spent working, and thus 
amounts to approximately $46.45 per year (approximately 5.0% of the annual minimum wage). 
4.1 Study Limitations 
The empirical data collected in this study provide a detailed description of the costs of HIV 
treatment and associated care at publicly funded outpatient clinics in Kenya. However, a number 
of limitations constrained the use of these data. 
4.1.1 Program Cost Assessment 
The empirical data collected in this study provide a detailed description of the costs of HIV 
treatment and associated care at publicly funded outpatient clinics in Kenya. However, a number 
of limitations constrained the use of these data. 
First, the study does not consider the off-setting savings that may result from providing effective 
treatment and, therefore, does not estimate the true net costs of HIV treatment programs—that is, 
the incremental cost of services after subtracting the cost savings associated with ART patients 
having less frequent episodes of illness or hospitalization and being more able to continue 
working or undertaking other productive activity. These cost savings may be considerable, and 
the net costs of treatment programs would be much lower if these costs savings were considered 
(Badri et al., 2006). However, the beneficiaries of reduced health care usage and greater personal 
productivity are the broader health care system and the patient, respectively, and these gains do 
not reduce the total funding requirements to support HIV treatment programs.  
Second, the study does not consider treatment outcomes. While a detailed description is given of 
the intensity of patient follow-up and the comprehensiveness of the care package, this 
information cannot address treatment quality or the value being generated by program funding. 
On the basis of partial information, it might be tempting to conclude that a cheaper program 
The Cost of Comprehensive HIV Treatment in Kenya 
 
August 2013 Page 44 of 48 
model would be preferable to a more expensive one, yet it is very possible that the outcomes 
generated by a more comprehensive model would justify the increased cost. For this reason, the 
study provides information on the current level of HIV treatment funding, but cannot draw 
conclusions about what the optimal resource level for HIV treatment funding should be.  
Third, it is important to consider the sample size and sample selection methods when gauging the 
generalizability of these findings. While a sample of 29 sites is large for a cost study of this type, 
it is small when compared with the sample sizes normally required to apply normal statistical 
measures of confidence (such as 95.0% confidence intervals). What is certain is that while the 
results may be valid estimates of costs for the typical HIV treatment clinic, they cannot reflect 
the costs of all treatment clinics. Costs varied widely among the sites in the sample, with 
individual sites costing substantially more or substantially less than the median.  
4.1.2 Patient Cost Assessment 
Although any sample is vulnerable to bias from unknown sources, any possible problems due to 
appointment scheduling (e.g., Monday versus Wednesday) were taken into consideration in the 
patient level sampling. One known source of bias is that this sampling strategy may oversample 
those patients who attend the clinic more frequently (since more frequent clinic attendees have a 
higher probability of attending the clinic during data collection, and thus have a higher 
probability of inclusion). While this has the potential to overestimate patient costs in the general 
patient population (patients incur costs to attend the clinic, and more frequent attendance could 
result in higher costs), the strategies required to prevent this bias (e.g., home-based follow-up of 
a randomized patient sample) were not feasible for the present study. The results are presented in 
the following section. 
On similar note, it is important to keep in mind that only patients who continue to travel to the 
clinic are sampled. As such one can draw only limited conclusions when using this data in the 
evaluation of patient demand characteristics. Loss due to follow-up is an issue in Kenya, as it is 
in many other countries. In addition to social factors, cost is undoubtedly a barrier for some 
patients. Due to the sampling approach, identifying this patient group and evaluating what the 
cost barrier is unknowable as these patients are not coming to the clinics. A sampling approach 
that would have included patients that have stopped treatment was not possible due to funding 
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and logistical constraints. As this is likely to remain an issue, further work is highly encouraged 
and needed on this front. 
4.2 Recommendations 
On the basis of the results of this study, the following recommendations may be helpful to 
consider: 
1)  Provide successful and cost-effective treatment: It’s important to recognize the main cost 
drivers (i.e., buffer stock, personnel, and laboratory) so that inefficiencies can be addressed 
in order of importance and relevance to the program. Further exploration of observed 
heterogeneity of clinical models (e.g., number if clinical staff per person, drug regimens, 
intensity of follow-up and laboratory services) across sites will allow an in-depth analysis 
of variation of costs across sites. 
2) Increase awareness of program costs: Expanding this study and carrying out similar ones 
across other HIV programs can provide a deeper understanding of the effort and resources 
needed for optimal treatment. Data can be used for modeling, forecasting, and planning for 
future treatment models. Consistent with previous research, study found that the main cost 
drivers were ARV drugs, personnel and laboratory tests.  Changes in national guidelines 
and/or unit costs of those inputs or guidelines are likely to have large effects on per patient 
costs.  For example, a sample scenario that considers replacement of Stavudine with 
Zidovudine, predicted 20% increase of the median cost per ART patient, and decreased 
variation in costs across sites. Study also found that viral load testing is not done 
routinely in many facilities. An in increase in regular utilization of viral load testing is 
likely to lead to significant increases in per patient costs. Government of Kenya and 
international funders should consider sensitivity of findings to such changes in their 
planning processes. 
3) Expand the scope of the evaluation: by covering treatment quality and outcomes (i.e., cost-
effectiveness analysis) to provide policymakers with key information for the decision-
making process. The variation in per patient costs and clinical models documented by the 
study should be considered in conjunction with potential variation in clinical outcomes 
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across facilities.  Examples of such studies include assessments of cost-effectiveness of 
more frequent patient follow-up and regular utilization of viral load testing. 
4) Create awareness on service barriers: This study shows that even though treatment is 
mostly provided for free, patients incur a cost to reach available services/treatment. 
Therefore, some policy changes focused on implementing strategies to offset out-of-pocket 
costs for patients from lower socio-economic groups may be beneficial (e.g. bringing 
services closer to patients, drug pick-up zones). 
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APPENDIX 1. D4T TO AZT SCENARIO 
WHO recommends that countries phase out the use of Stavudine, because of its long-term, 
irreversible side-effects, and Zidovudine or Tenofovir are recommended as less toxic and equally 
effective alternatives.  Tables below present select findings from a theoretical scenario, where all 
Stavudine is replaced with Zidovudine, The numbering of tables corresponds to that of the main 
body of the report. As demonstrated in Table 9a, replacement of Stavudine with Zidovudine 
results in median economic cost per patient of $292.71, an over $50 increase relative to the 
estimates presented in Table 9 of the report.  Additionally, the range of per patient costs across 
facilities is smaller, demonstrating that some of the variation in costs was due to variation in the 
utilization of Stavudine across facilities. 
 
TABLE 9A. MEDIAN COST PER PATIENT-YEAR, BY PATIENT TYPE (ECONOMIC COSTS, 2011 USD) 
Total Cost Pre-ART All ART 
Newly 
Initiated 
Adult ART 
Established 
Adult ART 
Newly 
Initiated 
Pediatric 
ART 
Established 
Pediatric 
ART 
Including 
ARVs 
Min $51.68 $224.65 $237.76 $227.03 $140.57 $131.78 
Max $250.25 $435.67 $557.37 $431.09 $619.21 $608.36 
Median $116.71 $292.71 $301.07 $287.51 $318.73 $295.04 
Excluding 
ARVs 
Min $51.68 $47.77 $62.46 $46.95 $62.46 $46.95 
Max $250.25 $260.09 $368.42 $259.00 $368.42 $259.00 
Median $116.71 $120.72 $148.34 $120.72 $136.39 $123.59 
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Table 10a shows the distribution of median annual economic costs across the different input 
types, subdivided into recurrent costs and investments. The costs of dispensed ARVs and cost of 
personnel were the most important cost components for ART patients, while for pre-ART 
patients, personnel and laboratory supplies were the dominant cost components. 
 
TABLE 10A. MEDIAN COST PER PATIENT-YEAR, BY INPUT TYPE (ECONOMIC COSTS, 2011 USD) 
Input Types 
Pre-ART 
Patients 
All ART 
Newly 
Initiated 
Adult 
ART 
Patients 
Established 
Adult ART 
Patients 
Newly 
Initiated 
Pediatric 
ART 
Patients 
Established 
Pediatric 
ART 
Patients 
R
e
c
u
rr
e
n
t 
C
o
s
ts
 
Personnel $36.95 $38.44 $43.71 $36.47 $43.71 $36.47 
Dispensed ARVs - $171.19 $168.71 $168.71 $181.53 $181.53 
Other drugs $8.51 $8.51 $8.51 $8.51 $8.51 $8.51 
Laboratory supplies $19.96 $19.30 $19.96 $19.30 $21.11 $19.33 
Other supplies $12.96 $13.57 $16.23 $12.60 $17.95 $12.60 
Building use $6.88 $7.70 $9.88 $7.70 $9.88 $7.70 
Travel $0.38 $0.40 $0.65 $0.38 $0.65 $0.38 
Utilities $1.06 $1.09 $1.09 $1.08 $1.09 $1.08 
Contracted services $2.95 $2.97 $3.04 $2.96 $3.04 $2.96 
ALL RECURRENT 
COSTS* 
$112.38 $290.96 $300.19 $280.72 $313.17 $293.33 
In
v
e
s
tm
e
n
ts
 Equipment $1.36 $1.38 $1.40 $1.37 $1.40 $1.37 
Training $1.29 $1.29 $1.29 $1.29 $1.29 $1.29 
New infrastructure $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 
ARV buffer stock - $0.62 $0.62 $0.62 $0.51 $0.51 
ALL INVESTMENTS* $2.81 $3.46 $3.56 $3.46 $3.63 $3.63 
TOTAL COST* $116.71 $292.71 $301.07 $287.51 $318.73 $295.04 
* Since median costs are presented, the sum of median costs for each input type will not equal median total costs. 
 
 
As demonstrated in Table 11a, clinical care comprised the largest cost category for ART patients, 
due to the cost of ARVs, while laboratory costs were also not trivial. Clinical care services 
comprised the largest cost component for pre-ART patients. Comparison between ART and pre-
ART patients showed that laboratory costs were roughly equal between the two groups. 
The Cost of Comprehensive HIV Treatment in Kenya 
 
August 2013 Appendix ● Page 3 of 3 
TABLE 11A. MEDIAN COST PER PATIENT-YEAR, BY PROGRAM ACTIVITY  
(ECONOMIC COSTS, 2011 USD) 
Program Activity 
Pre-ART 
Patients 
All ART 
Patients 
Newly 
Initiated 
Adult 
ART 
Patients 
Established 
Adult ART 
Patients 
Newly 
Initiated 
Pediatric 
ART 
Patients 
Established 
Pediatric 
ART 
Patients 
Training and supervision $1.29 $1.29 $1.29 $1.29 $1.29 $1.29 
Clinical care (excluding ARVs) $44.57 $36.77 $54.86 $36.77 $54.86 $41.14 
Clinical care (ARVs) --- $156.31 $153.66 $153.66 $165.34 $165.34 
Laboratory services $19.96 $19.30 $19.96 $19.30 $21.11 $19.33 
Supply chain management 
(excluding ARVs) --- $7.95 $7.95 $7.95 $7.95 $7.95 
Supply chain management 
(ARVs) 
--- 
$0.56 $0.57 $0.57 $0.47 $0.47 
M&E and HMIS $6.90 $6.90 $6.90 $6.90 $6.90 $6.90 
General administration and 
operations $13.53 $13.53 $13.53 $13.53 $13.53 $13.53 
TOTAL COST* $116.71 $292.71 $301.07 $287.51 $318.73 $295.04 
* Since median costs are presented, the sum of median costs for each category will not equal median total costs. 
 
 
  
 
